Abstract | OBJECTIVE: BACKGROUND: METHODS: A randomized, double-blind, parallel comparison of olanzapine and clozapine in patients with PD with chronic hallucinations was conducted. The primary outcome measure was the Scale for the Assessment of Positive Symptoms (SAPS) for psychotic symptoms. The Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale was used as a secondary outcome measure and as a safety monitoring tool. RESULTS: After 15 patients had completed the study, safety stopping rules were invoked because of exacerbated parkinsonism in olanzapine-treated subjects. UPDRS motor impairment scores from baseline to study end significantly increased with olanzapine treatment, and change scores between the olanzapine and clozapine groups significantly differed. The primary clinical domains responsible for the motor decline were gait and bradykinesia. Even with a smaller patient number than originally anticipated, clozapine significantly improved hallucinations and overall behavioral assessment, whereas olanzapine had no effect. CONCLUSIONS:
|
Authors | C G Goetz, L M Blasucci, S Leurgans, E J Pappert |
Journal | Neurology
(Neurology)
Vol. 55
Issue 6
Pg. 789-94
(Sep 26 2000)
ISSN: 0028-3878 [Print] United States |
PMID | 10993997
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzodiazepines
- Pirenzepine
- Clozapine
- Olanzapine
|
Topics |
- Aged
- Behavior
(drug effects, physiology)
- Benzodiazepines
- Clozapine
(administration & dosage, therapeutic use)
- Double-Blind Method
- Female
- Hallucinations
(drug therapy)
- Humans
- Male
- Middle Aged
- Movement
(drug effects, physiology)
- Olanzapine
- Parkinson Disease
(drug therapy, physiopathology)
- Pirenzepine
(administration & dosage, analogs & derivatives, therapeutic use)
|